Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-02-05 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
S-8 POS Filing
Regulatory Filings
2026-02-05 English
Communiqué de presse : Sanofi annonce la signature d’un mandat de rachat d'actions pour un montant maximum de 1 milliard d’euros
Transaction in Own Shares Classification · 100% confidence The document is a press release from Sanofi announcing the signing of a mandate to repurchase its own shares for a maximum amount of 1 billion euros. This falls directly under the category of 'Transaction in Own Shares' (POS), which covers share buyback announcements.
2026-02-03 French
Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion
Transaction in Own Shares Classification · 100% confidence The document is a press release announcing that Sanofi has signed a mandate to repurchase its own shares for up to €1 billion. This falls directly under the category of a company buying back its own shares, which is classified as 'Transaction in Own Shares' (POS).
2026-02-03 English
Communiqué de presse : Le CHMP recommande l'approbation du Rezurock de Sanofi dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing a positive recommendation from the CHMP (Committee for Medicinal Products for Human Use) regarding the approval of their drug 'Rezurock'. It details the clinical study results (ROCKstar), the regulatory context, and provides contact information for investor and media relations. It does not constitute a formal financial report, audit, or proxy statement, but rather a corporate regulatory announcement regarding product development and regulatory status. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-01-30 French
Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing a positive opinion from the European Medicines Agency's CHMP regarding the conditional marketing authorization of a drug (Rezurock). It provides details on clinical study results, regulatory status, and forward-looking statements. As it is a general regulatory announcement regarding product development and regulatory status that does not fit into specific financial reporting categories like earnings releases or annual reports, it is classified as a Regulatory Filing (RNS).
2026-01-30 English
Communiqué de presse : 2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026
Earnings Release Classification · 100% confidence The document is a press release from Sanofi titled '2025 : année de forte croissance du chiffre d'affaires et du BNPA'. It provides a detailed summary of the company's financial performance for the fourth quarter and the full fiscal year 2025, including revenue, net income, earnings per share (BNPA), and operational highlights. It also includes forward-looking guidance for 2026. This document is the primary announcement of financial results, which fits the definition of an Earnings Release (ER). Q4 2025
2026-01-29 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.